The Turkish Medicines and Medical Devices Agency published substantial revisions to its guideline on package information and patient information leaflets (PILs) for human medicinal products on March 19, 2026, with applicability starting March 18, 2026. The update affects all pharmaceutical market authorization holders in Türkiye, covering both prescription (Rx) and over-the-counter (OTC) medicines, and introduces phased compliance requirements through 2027.
Details of the Update
The revised guidance introduces significant changes to packaging design and patient information leaflets, including updates to readability standards, Braille requirements, content hierarchy, and disclosure of auxiliary substances. These changes require companies to review and update product artwork and PILs to ensure compliance with the new format and content expectations.
New requirements also mandate the use of differentiation and warning symbols for specific product categories, including psychotropics, narcotics, and high-risk medicines. These symbols must follow defined iconography standards, with phased enforcement timelines depending on product type and risk classification.
In addition, the guidance introduces mandatory digital components, including electronic leaflets (e-KT) and multimedia QR codes for most products. These requirements increase the need for robust digital content management systems and ongoing updates to ensure compliance across product lifecycles.
Deadline
Key deadlines include July 1, 2026, by which expanded requirements such as risk pictograms and anti-tampering features must be implemented, and January 1, 2027, when e-leaflets (e-KT) and multimedia QR codes become mandatory for most human medicinal products.
Why It Matters
This update introduces greater regulatory clarity around packaging and patient communication while aligning with digital transformation initiatives in the pharmaceutical sector. The inclusion of standardized iconography and electronic leaflets supports improved patient understanding and accessibility, while phased deadlines help balance compliance efficiency with implementation feasibility. However, the expanded scope also increases operational complexity and compliance risk if not addressed in a timely manner.
Who This Affects
This update is relevant for Regulatory Affairs, Quality Assurance, Packaging, IT, and Product Compliance teams within pharmaceutical companies marketing Rx and OTC products in Türkiye, particularly those responsible for labeling, artwork management, and digital content systems.
Next Steps
Organizations should initiate cross-functional reviews of existing packaging, PILs, and digital workflows to identify gaps against the revised requirements. Teams should prioritize updates based on phased deadlines, ensuring timely implementation of risk pictograms, anti-tampering features, and e-leaflet systems to avoid regulatory delays or enforcement actions.
As regulatory requirements become more complex and digitally driven, solutions that enable proactive compliance and workflow orchestration are increasingly critical. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including life sciences, to navigate evolving requirements such as those introduced by TITCK. By combining advanced AI with expert validation, RegASK delivers timely, predictive, and actionable insights, helping teams streamline updates to labeling, packaging, and digital compliance processes across more than 160 countries. Learn more or book a demo now.
FAQs
What did TITCK update in March 2026?
TITCK updated its guideline on package information and patient information leaflets (PILs), introducing new technical, content, and digital requirements for human medicinal products.
What are the key compliance deadlines?
The main deadlines are July 1, 2026 for risk pictograms and anti-tampering features, and January 1, 2027 for mandatory e-leaflets (e-KT) and QR codes.
Who is affected by the updated guideline?
All pharmaceutical companies marketing Rx and OTC medicines in Türkiye, including market authorization holders, must comply.
How can RegASK help with TITCK compliance updates?
RegASK helps organizations track regulatory changes, assess impact, and coordinate cross-functional updates, enabling efficient compliance with evolving requirements such as packaging updates, PIL revisions, and digital leaflet implementation.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
